worldwide offices | contact | help | sitemap

 

 

 

 

Newsroom

Newsroom

Meningitis B (MenB) Vaccination Programs at Princeton University and University of California, Santa Barbara (UCSB)

Novartis discovered and developed Bexsero®, (Meningococcal Group B Vaccine [rDNA, component, adsorbed]), the first and only broad coverage MenB vaccine to help protect all age groups against this disease.

Bexsero is licensed in Europe, Canada and Australia and was approved for use in the United States under a treatment Investigational New Drug (IND) designation. Nearly 30,000 doses have been distributed to Princeton University and UCSB, and more than 14,000 people have been vaccinated, adding to the increased use of Bexsero globally.

Novartis plans to file for US licensure of Bexsero as early as Q2 of 2014. The exact timing of this process depends on guidance from the US Food and Drug Administration (FDA). On April 1, 2014, the FDA granted Bexsero a Breakthrough Therapy designation, which is intended to expedite the development and review of new medicines that treat serious or life-threatening conditions. This designation includes all of the fast-track program features, as well as more intensive FDA guidance.


Relevant Media Releases


Relevant Links

CDC - Serogroup B Meningococcal Vaccine Questions and Answers

 

 

Fact Sheets on Bexsero and Meningococcal Disease

US Meningococcal Disease Fact Sheet

Bexsero Fact Sheet


Meningococcal Disease Fact Sheet


Untold Toll of Meningococcal Disease Fact Sheet


Value of Vaccines Fact Sheet


 

 

Infographics

Bexsero R&D Timeline

Meningococcal Disease: A Story by Numbers

 

 

Images

Bexsero Logo

Bexsero Logo

All rights reserved.

Bexsero Package Image

Bexsero Package Image

All rights reserved.

Bexsero Package Image

Bexsero Package Image 2

All rights reserved.

Bexsero Package Image

Bexsero Package Image 3

All rights reserved.

Bexsero Package Image

Bexsero Package Image 4

All rights reserved.

Meningitis Bacteria

Meningitis Bacteria

All rights reserved.

 

About Novartis Vaccines

vaccines

Novartis Vaccines is the world's fifth-largest vaccines business.